| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/07/2002 | WO2002009815A2 New pharmaceutical composition |
| 02/07/2002 | WO2002009768A2 Therapeutic polyesters and polyamides |
| 02/07/2002 | WO2002009742A1 Method for treating a pancreatic disorder with a neurotoxin |
| 02/07/2002 | WO2002009716A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | WO2002009714A1 Compositions and methods for the treatment of anorectal disorders |
| 02/07/2002 | WO2002009694A1 Anticonvulsant derivatives useful for the treatment of depression |
| 02/07/2002 | WO2002009690A2 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent |
| 02/07/2002 | WO2002009637A2 Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome |
| 02/07/2002 | WO2002009537A2 Alpha- (1, 4) linked glucose polymers containing oral compositions to alleviate or prevent tooth damage |
| 02/07/2002 | WO2001081310A8 1-aroyl-piperidinyl benzamidines |
| 02/07/2002 | WO2001060806A3 Substituted arylpyrazines |
| 02/07/2002 | WO2001059127A3 Drug metabolizing enzymes |
| 02/07/2002 | WO2001044294A3 Compositions and methods for inhibiting endothelial cell proliferation |
| 02/07/2002 | WO2001042449A3 Methods for introducing genes into mammalian subjects |
| 02/07/2002 | US20020016442 Hepatitis C inhibitor tri-peptides |
| 02/07/2002 | US20020016370 A therapeutically effective amount of exo-R-mecamylamine or salt, substantially free of exo-S-mecamylamine in combination with a carrier; useful for treating substance addiction |
| 02/07/2002 | US20020016368 Administering to a mammal a therapeutically effective amount of a compound of sulfonamide or alkanoy or amide derivative containing hetero or aromatic rings to treat osteoporosis, osteotomy, childhood idiopathic boen loss etc. |
| 02/07/2002 | US20020016354 Treatment of respiratory diseases, convulsions, vascular disorders, renal disorders, urinary disorders, Alzheimer's disease, dysmenorrhea, narcolepsy |
| 02/07/2002 | US20020016347 Benzophenones as inhibitors of IL-1beta and TNF-alpha |
| 02/07/2002 | US20020016342 Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 02/07/2002 | US20020016336 Treatment of rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration, tumor metastasis or invasion, periodontal disease and bone disease |
| 02/07/2002 | US20020016328 Corticotropin releasing factor antagonists |
| 02/07/2002 | US20020016322 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use |
| 02/07/2002 | US20020016301 Preventing or treating emesis associated with a macrolide antibiotic comprising administering a Substance P antagonist, such as (2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3 -trifluromethoxylphenyl)piperidine |
| 02/07/2002 | US20020016291 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
| 02/07/2002 | US20020015990 Nutrient broth for use in the propagation of preferential microorgansim and generation of foods |
| 02/07/2002 | US20020015981 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 02/07/2002 | DE10036818A1 Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten New N-triazolylmethyl piperazine derivatives as neurokinin receptor antagonists |
| 02/07/2002 | DE10005853C1 Verfahren zur Herstellung von Bis-(4-amino-1-pyridinium)-alkanen Alkanes process for the preparation of bis (4-amino-1-pyridinium) |
| 02/07/2002 | CA2771263A1 Therapeutic polyesters and polyamides |
| 02/07/2002 | CA2417848A1 Compositions and methods for the treatment of anorectal disorders |
| 02/07/2002 | CA2417719A1 Improved virus like particles based on small envelope protein from hepatitis b (hbsag-s) |
| 02/07/2002 | CA2417650A1 Indazole derivatives as jnk inhibitors and compositions and methods related thereto |
| 02/07/2002 | CA2417638A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor |
| 02/07/2002 | CA2417612A1 C3b/c4b complement receptor-like molecules and uses thereof |
| 02/07/2002 | CA2417568A1 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| 02/07/2002 | CA2417533A1 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent |
| 02/07/2002 | CA2417444A1 Nonsteroidal inflammation inhibitors |
| 02/07/2002 | CA2417359A1 Protein phosphatases |
| 02/07/2002 | CA2417356A1 Directed differentiation of embryonic cells |
| 02/07/2002 | CA2417349A1 Novel proteins and nucleic acids encoding same |
| 02/07/2002 | CA2417304A1 Anticonvulsant derivatives useful for the treatment of depression |
| 02/07/2002 | CA2417254A1 N-¢5-¢¢¢5-alkyl-2-oxazolyl!methyl!thio!-2-thiazolyl! carboxamide inhibitors of cyclin dependent kinases |
| 02/07/2002 | CA2417204A1 Imidazolyl derivatives |
| 02/07/2002 | CA2417195A1 G-protein coupled receptors |
| 02/07/2002 | CA2417059A1 3-substituted isoquinolin-1-yl derivatives |
| 02/07/2002 | CA2416978A1 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | CA2415851A1 Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 02/07/2002 | CA2385908A1 Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers |
| 02/06/2002 | EP1178115A2 Phosphodiesterase |
| 02/06/2002 | EP1178104A1 Use of essential oils for combatting GI tract infection by helicobacter-like organisms |
| 02/06/2002 | EP1178048A1 Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists |
| 02/06/2002 | EP1178047A1 Diazabicyclooctane derivatives and therapeutic uses thereof |
| 02/06/2002 | EP1178034A1 Alkyl amino acid derivatives useful as pharmaceutical agents |
| 02/06/2002 | EP1177796A1 Preventives/remedies for liver diseases |
| 02/06/2002 | EP1177794A2 Composition, containing lactobacillus bulgaricus and streptococcus thermophilus, for the treatment of gastrointestinal disorders, hyperlipidemia, autoimmune diseases, and obesity |
| 02/06/2002 | EP1177791A2 Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| 02/06/2002 | EP1177312A2 Human gil-19/ae289 proteins and polynucleotides encoding same |
| 02/06/2002 | EP1177296A2 Extracellular matrix and adhesion-associated proteins |
| 02/06/2002 | EP1177293A1 Growth factor homolog zvegf4 |
| 02/06/2002 | EP1177290A2 Recombinant laminin 5 |
| 02/06/2002 | EP1177287A2 Secreted human proteins |
| 02/06/2002 | EP1177212A1 Lawsonia derived gene and related sodc polypeptides, peptides and proteins and their uses |
| 02/06/2002 | EP1177210A1 Peptides from the tt virus sequence and monospecific antibodies binding to the tt virus |
| 02/06/2002 | EP1177204A2 Eplerenone crystalline form exhibiting enhanced dissolution rate |
| 02/06/2002 | EP1177197A2 Polyamines and their use in therapy |
| 02/06/2002 | EP1177195A1 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/06/2002 | EP1177181A1 Substituted bicyclic compounds |
| 02/06/2002 | EP1177175A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/06/2002 | EP1177168A1 Caspase inhibitors and the use thereof |
| 02/06/2002 | EP1176985A2 Enzymatically activated polymeric drug conjugates |
| 02/06/2002 | EP1176982A1 Prucalopride oral solution |
| 02/06/2002 | EP1176981A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| 02/06/2002 | EP1176980A1 Ccr4 antagonists in sepsis |
| 02/06/2002 | EP1176972A1 Use of phyllanthus for targeted stimulation of the immune system |
| 02/06/2002 | EP1176971A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes |
| 02/06/2002 | EP1176965A1 Antisense modulation of fas mediated signaling |
| 02/06/2002 | EP1176963A2 Use of dopamine d 3? receptor ligands for producing medicaments for treating kidney disorders |
| 02/06/2002 | EP1176956A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/06/2002 | EP1176948A1 Anti-nausea compositions and methods |
| 02/06/2002 | EP1176870A2 Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| 02/06/2002 | EP1162990A4 Treatment with small peptides to effect antifibrotic activity |
| 02/06/2002 | EP0971917B1 Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties |
| 02/06/2002 | EP0966256B1 Agents for promoting oral hygiene and oral health |
| 02/06/2002 | EP0815868B1 A chinese drug composition for treatment of peptic ulcer |
| 02/06/2002 | CN1334830A Hydrophilic ampholytic polymer |
| 02/06/2002 | CN1334821A Humanized antibodies to gamma-interferon |
| 02/06/2002 | CN1334820A Connective tissue growth factor fragments and methods and uses thereof |
| 02/06/2002 | CN1334819A Connective tissue growth factor fragments and methods and uses thereof |
| 02/06/2002 | CN1334815A Methotrexate derivatives |
| 02/06/2002 | CN1334813A Method for preparing (R)-(+)-3-{1-[2-(4-benzoyl-2-(3,4-difluorophenyl) morpholin-2-yl)ethyl]-4-phenylpiperdin-4-yl}-1,1-dimethylurea, its salts solvates and/or hydrates |
| 02/06/2002 | CN1334812A Piperazine derivatives |
| 02/06/2002 | CN1334809A Nonsteroidal antiinflammatories |
| 02/06/2002 | CN1334808A Benzamide derivs. and their use as APOB-100 secretion inhibitors |
| 02/06/2002 | CN1334807A 1-heterocycle substd. diarylamines |
| 02/06/2002 | CN1334797A 3,4-diamino-3-cyclobutene-1,2-dione derivs. which inhibit leukocyte adhesion mediated by VLA-4 |
| 02/06/2002 | CN1334742A Method of using lanreotide as somatostatin analogue |
| 02/06/2002 | CN1334736A Modulation of immune response by ribavirin |
| 02/06/2002 | CN1334731A Pharmaceutical formulation |
| 02/06/2002 | CN1334730A Vitronectin receptor antagonist |